share_log

Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

Nexgel (NXGL) Sees Recovery On US Stock Charts Following Record Quarterly Revenue

Nexgel(NXGL)在創紀錄的季度營業收入後,在美國股票圖表上看到復甦
Stocks Telegraph ·  07/09 13:15

Shares of Nexgel, Inc. (NASDAQ: NXGL) experienced a notable recovery on the US stock charts following the market close on Monday, driven by record revenue figures. During the after-market session, NXGL stock surged by 17.16% to reach $2.39, recovering from a regular-session loss of -7.69%.

根據市場的最新營業收入數據,Nexgel公司(納斯達克代碼:NXGL)在週一收盤後在美國股票交易市場上經歷了顯著的復甦,股票價格大漲17.16%,達到2.39美元,恢復了常規交易會議中的-7.69%的損失。

Table of Contents

目錄

Toggle
切換
  • Quarterly Revenue of
  • Nexgel
  • Future Outlook
  • Strategic Partnership with Cintas Corporation
  • 營業收入季報
  • Nexgel
  • 未來展望
  • Cintas公司戰略合作伙伴關係

Quarterly Revenue of

Nexgel營業收入季報

Nexgel

Nexgel

Nexgel announced its preliminary, unaudited revenue for the second quarter of 2024 and provided revenue guidance for the third and fourth quarters of the same year. According to the preliminary data, Nexgel reported a second-quarter revenue of $1.4 million, marking an approximate 20% increase year-over-year and a 10% sequential growth.

Nexgel宣佈其第二季度的初步未經審計營業收入,並提供同年第三季度和第四季度的營業收入指導。根據初步數據,Nexgel報告第二季度營業收入達140萬美元,同比增長約20%,環比增長10%。

The company also anticipates a significant year-over-year increase of 83% in Q3 2024, projecting revenues of $2.2 million. Nexgel anticipates growth in the second half of this year, which puts the firm in a strong position to transition to positive cash flow from operations, even if the Q3 estimate does not yet include any revenue from its collaboration with AbbVie.

該公司還預計,2024年第三季度年同比營業收入將大幅增長83%,預計營業收入爲220萬美元。Nexgel預計在今年下半年實現增長,這將使該公司處於強勁的轉正現金流的位置,即使第三季度的估計尚未包括其與AbbVie公司的合作的任何營業收入。

Future Outlook

未來展望

Despite facing lower-than-normal revenues at CG Converting and Packaging due to a move into a newly expanded facility, Nexgel delivered record revenue for the second quarter of 2024. The company provided an optimistic outlook for the second half of the year, surpassing expectations for both contract manufacturing and consumer products. The growth in contract manufacturing is attributed primarily to new customer relationships with large global corporations, while several NXGL brands are also experiencing substantial growth.

儘管由於進入新的擴建工廠而導致CG Converting and Packaging收入低於正常水平,但Nexgel公司仍然在2024年第二季度實現了創紀錄的營業收入。該公司對下半年的前景持樂觀態度,超過了合同製造和消費品的預期。合同製造的增長主要歸因於與大型全球公司的新客戶關係,而幾個NXGL品牌也在經歷着實質性的增長。

Strategic Partnership with Cintas Corporation

Cintas公司戰略合作伙伴關係

In a strategic business move, Nexgel announced a supply agreement with Cintas Corporation, a leading provider of corporate identity uniforms, first aid and safety products, and services to over one million businesses across North America. Through this partnership, Cintas will distribute SilverSeal, a hospital-grade hydrogel dressing for wounds and burns, to its customers across various sectors, including hospitality and public service.

在一項戰略性的商業舉措中,Nexgel宣佈與Cintas Corporation簽訂了供應協議,Cintas Corporation是北美領先的企業身份制服、急救和安全用品以及服務的供應商,向萬家企業提供服務。通過這一合作伙伴關係,Cintas將向其客戶分銷SilverSeal,一種醫用級別的水凝膠敷貼,用於治療創傷和燒傷,包括酒店和公共服務等各種領域。

NXGL expects the first order of SilverSeal to be delivered during the fourth quarter of 2024. This partnership is significant for Nexgel, not only for the associated revenue but also for enhancing brand awareness of SilverSeal.

NXGL預計SilverSeal的第一筆訂單將在2024年第四季度交付。這一合作伙伴關係對Nexgel來說非常重要,不僅因爲其相關的營業收入,而且還因爲增強了SilverSeal品牌的知名度。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論